ScoreWhy is Jiangsu Lianhuan Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 9.67%
- The company has been able to generate a Return on Capital Employed (avg) of 9.67% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 15.27% and Operating profit at -163.13% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 10.90% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 15.27% and Operating profit at -163.13% over the last 5 years
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -22.90%, its profits have fallen by -207.6%
- At the current price, the company has a high dividend yield of 0
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Jiangsu Lianhuan Pharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
-24.26%
1.37
62.86%
China Shanghai Composite
0.9%
0.22
14.72%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
15.27%
EBIT Growth (5y)
-163.13%
EBIT to Interest (avg)
5.47
Debt to EBITDA (avg)
7.11
Net Debt to Equity (avg)
0.70
Sales to Capital Employed (avg)
0.94
Tax Ratio
12.90%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.37%
ROE (avg)
10.90%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.18
EV to EBIT
-352.36
EV to EBITDA
88.87
EV to Capital Employed
2.00
EV to Sales
1.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.57%
ROE (Latest)
-8.15%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
NET SALES(HY)
At CNY 1,570.81 MM has Grown at 22.74%
NET PROFIT(Q)
At CNY 4.1 MM has Grown at 106.49%
CASH AND EQV(HY)
Highest at CNY 551.34 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 3.53 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.76 times
OPERATING PROFIT(Q)
Highest at CNY 52.32 MM
OPERATING PROFIT MARGIN(Q)
Highest at 6.88 %
PRE-TAX PROFIT(Q)
Highest at CNY 14.54 MM
-12What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at 124.53 %
RAW MATERIAL COST(Y)
Grown by 15.42% (YoY
INTEREST(Q)
Highest at CNY 9.88 MM
Here's what is working for Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Pre-Tax Profit
At CNY 14.54 MM has Grown at 129.93%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 4.1 MM has Grown at 106.49%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Net Sales
At CNY 1,570.81 MM has Grown at 22.74%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 52.32 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 6.88 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 14.54 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Cash and Eqv
Highest at CNY 551.34 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 3.53 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.76 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Interest
At CNY 9.88 MM has Grown at 18.08%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Debt-Equity Ratio
Highest at 124.53 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Interest
Highest at CNY 9.88 MM
in the last five periods and Increased by 18.08% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Raw Material Cost
Grown by 15.42% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
